S&P 500   3,296.32 (-0.88%)
DOW   29,004.50 (-0.53%)
QQQ   222.91 (-0.75%)
AAPL   320.10 (+0.27%)
FB   217.65 (-0.96%)
MSFT   165.13 (-0.95%)
AMZN   1,860.10 (-1.30%)
CGC   22.96 (-6.51%)
NVDA   251.08 (-0.70%)
BABA   213.83 (-2.42%)
MU   57.90 (-2.20%)
GE   11.72 (-0.42%)
TSLA   562.09 (-1.77%)
AMD   50.22 (-2.88%)
T   38.41 (-0.60%)
ACB   1.99 (-3.86%)
F   9.01 (-1.42%)
NFLX   351.00 (+0.40%)
S&P 500   3,296.32 (-0.88%)
DOW   29,004.50 (-0.53%)
QQQ   222.91 (-0.75%)
AAPL   320.10 (+0.27%)
FB   217.65 (-0.96%)
MSFT   165.13 (-0.95%)
AMZN   1,860.10 (-1.30%)
CGC   22.96 (-6.51%)
NVDA   251.08 (-0.70%)
BABA   213.83 (-2.42%)
MU   57.90 (-2.20%)
GE   11.72 (-0.42%)
TSLA   562.09 (-1.77%)
AMD   50.22 (-2.88%)
T   38.41 (-0.60%)
ACB   1.99 (-3.86%)
F   9.01 (-1.42%)
NFLX   351.00 (+0.40%)
S&P 500   3,296.32 (-0.88%)
DOW   29,004.50 (-0.53%)
QQQ   222.91 (-0.75%)
AAPL   320.10 (+0.27%)
FB   217.65 (-0.96%)
MSFT   165.13 (-0.95%)
AMZN   1,860.10 (-1.30%)
CGC   22.96 (-6.51%)
NVDA   251.08 (-0.70%)
BABA   213.83 (-2.42%)
MU   57.90 (-2.20%)
GE   11.72 (-0.42%)
TSLA   562.09 (-1.77%)
AMD   50.22 (-2.88%)
T   38.41 (-0.60%)
ACB   1.99 (-3.86%)
F   9.01 (-1.42%)
NFLX   351.00 (+0.40%)
S&P 500   3,296.32 (-0.88%)
DOW   29,004.50 (-0.53%)
QQQ   222.91 (-0.75%)
AAPL   320.10 (+0.27%)
FB   217.65 (-0.96%)
MSFT   165.13 (-0.95%)
AMZN   1,860.10 (-1.30%)
CGC   22.96 (-6.51%)
NVDA   251.08 (-0.70%)
BABA   213.83 (-2.42%)
MU   57.90 (-2.20%)
GE   11.72 (-0.42%)
TSLA   562.09 (-1.77%)
AMD   50.22 (-2.88%)
T   38.41 (-0.60%)
ACB   1.99 (-3.86%)
F   9.01 (-1.42%)
NFLX   351.00 (+0.40%)
Log in

NASDAQ:TYME - Tyme Technologies Stock Price, Forecast & News

$1.60
-0.05 (-3.04 %)
(As of 01/24/2020 03:14 PM ET)
Today's Range
$1.50
Now: $1.60
$1.75
50-Day Range
$1.00
MA: $1.36
$1.94
52-Week Range
$0.92
Now: $1.60
$3.42
Volume545,745 shs
Average Volume905,317 shs
Market Capitalization$178.77 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4
Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TYME
CUSIPN/A
Phone212-461-2315

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.09 per share

Profitability

Net Income$-32,980,000.00

Miscellaneous

Employees11
Market Cap$178.77 million
Next Earnings Date2/10/2020 (Estimated)
OptionableOptionable

Receive TYME News and Ratings via Email

Sign-up to receive the latest news and ratings for TYME and its competitors with MarketBeat's FREE daily newsletter.


Tyme Technologies (NASDAQ:TYME) Frequently Asked Questions

What is Tyme Technologies' stock symbol?

Tyme Technologies trades on the NASDAQ under the ticker symbol "TYME."

How were Tyme Technologies' earnings last quarter?

Tyme Technologies Inc (NASDAQ:TYME) issued its quarterly earnings results on Monday, November, 4th. The company reported ($0.04) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.02. View Tyme Technologies' Earnings History.

When is Tyme Technologies' next earnings date?

Tyme Technologies is scheduled to release their next quarterly earnings announcement on Monday, February 10th 2020. View Earnings Estimates for Tyme Technologies.

What price target have analysts set for TYME?

1 analysts have issued twelve-month price objectives for Tyme Technologies' stock. Their forecasts range from $10.00 to $10.00. On average, they expect Tyme Technologies' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 526.2% from the stock's current price. View Analyst Price Targets for Tyme Technologies.

What is the consensus analysts' recommendation for Tyme Technologies?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyme Technologies in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tyme Technologies.

What are Wall Street analysts saying about Tyme Technologies stock?

Here are some recent quotes from research analysts about Tyme Technologies stock:
  • 1. According to Zacks Investment Research, "Tyme Technologies, Inc. is a pharmaceutical company. The company is focused on creating medicines which specialize in the body's immune system to treat diseases. Tyme Technologies, Inc. is headquartered in New York. " (1/11/2020)
  • 2. HC Wainwright analysts commented, "We maintain our Buy rating of TYME and our 12-month price target of $9.50 per share. We derive our price target based on a net present value analysis of projected SM-88 revenues through FY2030, assuming a 12% discount rate and 2% terminal growth rate." (8/12/2019)

Has Tyme Technologies been receiving favorable news coverage?

Media stories about TYME stock have been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Tyme Technologies earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Tyme Technologies.

Are investors shorting Tyme Technologies?

Tyme Technologies saw a decrease in short interest in December. As of December 31st, there was short interest totalling 6,730,000 shares, a decrease of 5.2% from the December 15th total of 7,100,000 shares. Based on an average daily trading volume, of 448,600 shares, the short-interest ratio is currently 15.0 days. Currently, 13.1% of the company's stock are sold short. View Tyme Technologies' Current Options Chain.

Who are some of Tyme Technologies' key competitors?

What other stocks do shareholders of Tyme Technologies own?

Who are Tyme Technologies' key executives?

Tyme Technologies' management team includes the folowing people:
  • Mr. Steven E. Hoffman, Co-Founder, Chairman, CEO & Chief Science Officer (Age 56)
  • Mr. Ben R. Taylor, Pres & CFO (Age 42)
  • Mr. Michael S. Demurjian, Co-Founder, Exec. VP, COO & Director (Age 52)
  • Mr. James Biehl J.D., Chief Legal Officer & Sec. (Age 55)
  • Dr. Giuseppe Del Priore, Chief Medical Officer (Age 57)

How do I buy shares of Tyme Technologies?

Shares of TYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Tyme Technologies' stock price today?

One share of TYME stock can currently be purchased for approximately $1.60.

How big of a company is Tyme Technologies?

Tyme Technologies has a market capitalization of $178.77 million. The company earns $-32,980,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Tyme Technologies employs 11 workers across the globe.View Additional Information About Tyme Technologies.

What is Tyme Technologies' official website?

The official website for Tyme Technologies is http://www.tymeinc.com/.

How can I contact Tyme Technologies?

Tyme Technologies' mailing address is 17 STATE STREET 7TH FLOOR, NEW YORK NY, 10004. The company can be reached via phone at 212-461-2315 or via email at [email protected]


MarketBeat Community Rating for Tyme Technologies (NASDAQ TYME)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  175 (Vote Outperform)
Underperform Votes:  185 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about Tyme Technologies and other stocks. Vote "Outperform" if you believe TYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Featured Article: Market Indexes

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel